Eff ect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): A randomised, placebo-controlled, phase 2 trial

The Lancet

Volumn 383, Issue 9936, 2014, Pages 2213-2221

  Chataway, Jeremy ^a,b,c,e,f   Schuerer, Nadine ^d   Alsanousi, Ali ^e   Chan, Dennis ^g   MacManus, David ^b,c   Hunter, Kelvin ^b,c   Anderson, Val ^b,c   Bangham, Charles R M ^f   Clegg, Shona ^c   Nielsen, Casper ^c   Fox, Nick C ^a,c   Wilkie, David ^f   Nicholas, Jennifer M ^e   Calder, Virginia L ^d   Greenwood, John ^d   Frost, Chris ^h   Nicholas, Richard ^f,h  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^f IMPERIAL COLLEGE LONDON   (United Kingdom)

^g BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; SIMVASTATIN; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE SCALE; MULTIPLE SCLEROSIS IMPACT SCALE 29; MUSCLE CRAMP; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; PHYSICAL DISABILITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; ADOLESCENT; ATROPHY; BRAIN; CONTROLLED CLINICAL TRIAL; DISABLED PERSON; DOSE RESPONSE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOLOGY; YOUNG ADULT; DEPRESSION; DISABILITY; DRUG EFFECT; FRACTURE; LUNG EMBOLISM; NEUROSCIENCE; PHYSICIAN; PNEUMONIA; SEIZURE; SPASTICITY; SUBARACHNOID HEMORRHAGE; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VIRUS ENCEPHALITIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ATROPHY; BRAIN; CYTOKINES; DISABLED PERSONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; SIMVASTATIN; YOUNG ADULT;

EID: 84903318797     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)62242-4     Document Type: Article

References (58)

1. Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, Howell O. The neuropathological basis of clinical progr ession in multiple sclerosis. Acta Neuropathol 2011; 122: 155-70.
2. The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337: 441-46.
3. Ro varis M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006; 5: 343-54.
4. Mantia LL , Vacchi L, Rovaris M, et al. Interferon β for secondary progressive multiple sclerosis: a systematic review. J Neurol Neurosurg Psychiatry 2013; 84: 420-26.
5. Freedman MS, Bar-Or A, Oge r J, et al, and the MAESTRO-01 Investigators. A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. Neurology 2011; 77: 1551-60.
6. Kapoor R, Furby J, Hayt on T, et al. Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Neurol 2010; 9: 681-88.
7. Zajicek J , Ball S, Wright D, et al, and the CUPID investigator group. Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial. Lancet Neurol 2013; 12: 857-65.
8. Humphries C. Progressive multiple sclerosis: The treatment gap. Nature 2012; 484: S10.
9. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6: 358-70.
10. Greenwood J, Walters CE, Pryce G, et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 2003; 17: 905-07.
11. Weber MS, Youssef S, Dunn SE, et al. Statins in the treatment of central nervous system autoimmune disease. J Neuroimmunol 2006; 178: 140-48.
12. Zamvil SS, Steinman L. Cholesterol-lowering statins possess anti-infl ammatory activity that might be useful for treatment of MS. Neurology 2002; 59: 970-71.
13. van der Most PJ, Dolga AM, Nijholt IM, Luiten PGM, Eisel ULM. Statins: mechanisms of neuroprotection. Prog Neurobiol 2009; 88: 64-75.
14. Giannopoulos S, Katsanos AH, Tsivgoulis G, Marshall RS. Statins and cerebral hemodynamics. J Cereb Blood Flow Metab 2012; 32: 1973-76.
15. Greenwood J, Mason JC. Statins and the vascular endothelial infl ammatory response. Trends Immunol 2007; 28: 88-98.
16. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004; 363: 1607-08.
17. Togha M, Karvigh SA, Nabavi M, et al. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler 2010; 16: 848-54.
18. Sorensen PS, Lycke J, Erälinna JP, et al, and the SIMCOMBIN study investigators. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled ra ndomised phase 4 trial. Lancet Neurol 2011; 10: 691-701.
19. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multi ple sclerosis. Neurology 2008; 71: 1390-95.
20. Lanzillo R, Orefice G, Quarantelli M, et al. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple s clerosis patients: a longitudinal controlled trial of combination therapy. Mult Scler 2010; 16: 450-54.
21. Kamm CP, El-Koussy M, Humpert S, et al. Atorvastatin added to interferon β for relapsing multiple sclerosis: a randomized controlled trial. J Neurol 2012; 259: 2401-13.
22. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444-52.
23. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the " McDonald Criteria" . Ann Neurol 2005; 58: 840-46.
24. Lublin FD, Reingold SC, and the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46: 907-11.
25. ClinicalTrials.gov. Investigation of simvastatin in secondary progressive multiple sclerosis (MS-STAT). Nov 26, 2012. http://clinicaltrials.gov/ct2/show/ study/NCT00647348 (accessed Feb 17, 2013).
26. ICH Expert Working Group. ICH harmonized tripartite guidelines for good clinical practice: E6(R1). June 10, 1996. http://www.ich. org/fileadmin/Public- Web-Sit e/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/E6-R1-Guideline.pdf (accessed Feb 17, 2014).
27. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. (http://www.wma.net/en/ 30publications/10policies/b3/17c.pdf).
28. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975; 31: 103-15.
29. Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. IEEE Trans Med Imaging 1997 16 623-29 .
30. Leung KK, Clarkson MJ, Bartlett JW, et al, and the Alzheimer's Disease Neuroimaging Initiative. Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage 2010; 50: 516-23.
31. Anderson VM, Fernando KT, Davies GR, et al. Cerebral atrophy m easurement in clinically isolated syndromes and relapsing remitting multiple sclerosis: a comparison of registration-based methods. J Neuroimaging 2007; 17: 61-68.
32. Smith SM, Rao A, De Stefano N, et al. Longitudinal and cross-sectional analysis of atrophy in Alzheimer's disease: cross-validation of BSI, SIENA and SIENAX. Neuroimage 2007; 36: 1200-06.
33. Durand-Dubief F, Belaroussi B, Armspach J P, et al. Reliability of longitudinal brain volume loss measurements between 2 sites in patients with multiple sclerosis: comparison of 7 quantification techniques. AJNR Am J Neuroradiol 2012; 33: 1918-24.
34. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008; 71: 136-44.
35. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-82.
36. Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001; 124: 962-73.
37. Hill T, Galatowicz G, Akerele T, Lau CH, Calder V, Lightm an S. Intracellular T lymphocyte cytokine profiles in the aqueous humour of patients with uveitis and correlation with clinical phenotype. Clin Exp Immunol 2005; 139: 132-37.
38. Frost C, Kenward MG, Fox NC. The analysis of repeated 'direct'measures of change illustrated with an application in longitudinal imaging. Stat Med 2004; 23: 3275-86.
39. Little RJA, Rubin DB. Statistical analysis with missing data. Wiley: New York, 2002.
40. Frison LJ, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med 1992; 11: 1685-704.
41. Efron B, Tibshirani RJ. An introduction to the bootstrap. Chapman and Hall: London, 1993.
42. Davison AC, Hinkley DV. Bootstrap methods and their application. Cambridge University Press: Cambridge, 1997.
43. Breslow NE. Extra-poisson variation in log-linear models. Appl Stat 1984; 33: 38-44.
44. Frost C, Kenward MG, Fox NC. Optimizing the design of clinical trials where the outcome is a rate. Can estimating a baseline rate in a run-in period increase efficiency? Stat Med 2008; 27: 3717-31.
45. De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010; 74: 1868-76.
46. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59: 1412-20.
47. Hobart J, Freeman JA, Thompson AJ. Kurtzke scales revisited: the application of psychometric methods to clinical intuition. Brain 2000; 123: 1027-40.
48. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009; 5: 256-66.
49. Cohen JA, Reingold SC, Polman CH, Wolinsky JS, and the International Advisory Committee on Clinical Trials in Multiple Sclerosis. Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol 2012; 11: 467-76.
50. Wang J, Xiao Y, Luo M, Luo H. Statins for multiple sclerosis Cochrane Database Syst Rev 2011 12: CD008386.
51. Bhardwaj S, Coleman CI, Sobieraj DM. Efficacy of statins in combination with interferon therapy in multiple sclerosis: a meta-analysis. Am J Health Syst Pharm 2012; 69: 1494-99.
52. Waubant E, Pelletier D, Mass M, et al. Randomized controlled trial of atorvastatin in clinically isolated syndrome: the STAyCIS study. Neurology 2012; 78: 1171-78.
53. Tsakiri A, Kallenbach K, FugloD, Wanscher B, Larsson H, Frederiksen J. Simvastatin improves final visual outcome in acute optic neuritis: a randomized study. Mult Scler 2012; 18: 72-81.
54. Schmeer C, Kretz A, Isenmann S. Statin-mediated protective effects in the central nervous system: general mechanisms and putative role of stress proteins. Restor Neurol Neurosci 2006; 24: 79-95.
55. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
56. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA 1998; 95: 8880-85.
57. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8: 647-56.
58. Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology 2010; 74: 1041-47.